Non-Invasive Biomarkers Advance Early Detection, Screening of Lung, Urothelial Cancers

Lung cancer remains the leading cause of cancer deaths worldwide, with early detection critical for improving patient outcomes. Current screening methods, such as low-dose CT scans, are more sensitive than X-rays but can produce ambiguous results requiring further biopsy to confirm malignancy. New non-invasive diagnostic tools like bioAffinity Technologies' CyPath Lung test have demonstrated the ability to identify early-stage lung cancer even when traditional imaging and risk models suggest low risk, enabling timely surgical intervention. Additionally, a UK-based study is investigating a novel lung cancer risk assessment tool specifically for high-risk Hodgkin lymphoma survivors to enhance early detection and improve survival rates. Despite advances, there remains a need for more reliable biomarkers to improve early diagnosis and recurrence risk stratification, with research exploring urinary metabolomic profiles as a promising non-invasive source. These ongoing innovations across diagnostics aim to reduce the burden of lung cancer through improved screening and personalized care pathways.